These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
453 related items for PubMed ID: 15328081
1. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M. Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081 [Abstract] [Full Text] [Related]
4. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardière JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F. J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327 [Abstract] [Full Text] [Related]
6. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice. Bienvenu B, Krivine A, Rollot F, Pietri MP, Lebault V, Meritet JF, Guerin C, Spiridon G, Salmon D, Guillevin L, Lebon P, Launay O. J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284 [Abstract] [Full Text] [Related]
7. Resistance to enfuvirtide, the first HIV fusion inhibitor. Greenberg ML, Cammack N. J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762 [Abstract] [Full Text] [Related]
8. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy. Charpentier C, Jenabian MA, Piketty C, Karmochkine M, Tisserand P, Laureillard D, Bélec L, Si-Mohamed A, Weiss L. Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978 [Abstract] [Full Text] [Related]
9. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. Cabrera C, Marfil S, García E, Martinez-Picado J, Bonjoch A, Bofill M, Moreno S, Ribera E, Domingo P, Clotet B, Ruiz L. AIDS; 2006 Oct 24; 20(16):2075-80. PubMed ID: 17053353 [Abstract] [Full Text] [Related]
10. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. Su C, Melby T, DeMasi R, Ravindran P, Heilek-Snyder G. J Clin Virol; 2006 Aug 24; 36(4):249-57. PubMed ID: 16765082 [Abstract] [Full Text] [Related]
14. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy. Poveda E, Briz V, Paraskevis D, Barreiro P, Hatzakis A, Soriano V. AIDS Res Hum Retroviruses; 2007 Sep 24; 23(9):1078-82. PubMed ID: 17919101 [Abstract] [Full Text] [Related]
15. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. Marcial M, Lu J, Deeks SG, Ziermann R, Kuritzkes DR. J Clin Microbiol; 2006 Sep 24; 44(9):3384-7. PubMed ID: 16954280 [Abstract] [Full Text] [Related]